Compare Jabil Inc (JBL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs TransMedics Group Inc — how do they compare? Jabil Inc trades at $306.28 (market cap $31.35B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Jabil Inc is far larger — about 11.4× TransMedics Group Inc's market cap, and Jabil Inc pays a 0.11% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and TransMedics Group Inc for 24 Days on average.
| JBL | TMDX | |
|---|---|---|
Market Cap | $31.35B | $2.74B |
Volume | 1,337,978 | 949,331 |
Sector | Technology | Health |
52-Week High | $385.50 | $150.42 |
52-Week Low | $192.49 | $61.99 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $33.63B | $3.13B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.16, down 0.1% on the day, amid a bearish technical signal despite strong Q4 2026 earnings that beat estimates with EPS of $4.40. The stock shows robust fundamentals, including 74.11% ROE and a consensus analyst price target of $434.75, implying significant upside. Recent news highlights AI infrastructure demand driving growth, with fiscal 2027 revenue growth projected at 24%.
The outlook is positive due to accelerating AI demand and strong earnings momentum, but risks include high valuation multiples and market volatility. Analyst consensus is strongly bullish with no sell ratings, supporting a long-term growth narrative despite near-term technical weakness.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
